Hypometabolism is a hallmark of neurodegenerative disease, but is it merely a downstream consequence of accumulated pathology, or an active driver of disease progression? This talk explores emerging evidence that metabolic dysfunction may play a causal, and potentially targetable, role in neurodegeneration.
Steinunn Sara Helgudottir, Chief Scientific Officer, Neurometa Therapeutics
